Mount Sinai Lab Creates Shared Database to Help Scientists Find Drugs That Can Be Used to Treat COVID-19
As the public turns its attention to vaccine development in the hope of ending the COVID-19 pandemic, equally important work is taking place in the area of drug repurposing—identifying drugs already approved for other diseases that may also be...
Mount Sinai Leaders Explore COVID-19 Vaccines, Treatments, and the Path Ahead in Aspen Ideas: Health Panel Discussion
Does convalescent plasma therapy work? Is a successful vaccine for COVID-19 on the way? Will it be suitable for senior citizens and available to minority communities that were hardest hit by the pandemic? These pressing topics are explored in a recent...
Men Hospitalized for COVID-19 Were Younger and Healthier Than Women Who Were Hospitalized
Men who were hospitalized for COVID-19 in New York City during the early days of the pandemic were both younger and healthier on average than their female counterparts, according to a new study by researchers at the Icahn School of Medicine at Mount Sinai....
Vaccines for COVID-19: How Protective Are They? When Will They Be Ready? A Leading Vaccinologist at Mount Sinai Weighs In
As the SARS-CoV-2 virus circulates throughout the world unchecked, researchers are racing to develop more than 135 vaccines. How well will these vaccines work and how soon will we be able to benefit from them? To answer these questions and more, Mount...
Mount Sinai Research Shows That Children Have Lower Risk of Catching COVID-19
On Saturday, March, 14, as the U.S. economy was beginning to shut down due to the COVID-19 pandemic, Supinda Bunyavanich, MD, MPH, a mother of two young children and a Professor of Genetics and Genomic Sciences, and Pediatrics, at the Icahn School of...
How Researchers—Using Adhesive Skin Tape Strips—Found a Single Gene Biomarker to Distinguish Atopic Dermatitis From Psoriasis
An estimated 31 million adults, and between 10 and 20 percent of children in the United States, have atopic dermatitis (AD), a common skin disorder commonly known as eczema. Another 8 million U.S. adults have psoriasis. Both are chronic and complex...
Most People Mount a Strong Antibody Response to COVID-19
The majority of individuals with COVID-19—including those with mild infections—mount a robust antibody response that is stable for at least three months, according to a new study by researchers at the Icahn School of Medicine at Mount Sinai....
New Clinical Trial Will Test Whether Ketamine Can Be Used to Treat Children with Autism
Ketamine, an anesthetic medication that has also been approved for use in severe depression, is now offering promise to children with a form of autism known as ADNP syndrome, or Helsmoortel-Van Der Aa syndrome. Ten children, ages 5 to 12, will soon take part in a...
Mount Sinai to Create and Test New Hyperimmune Globulin Drug for COVID-19
The Mount Sinai Health System in July will begin collecting high levels of blood-based antibodies from people who have recovered from COVID-19 as part of a $34.6 million clinical trial to create and test a hyperimmune globulin drug that would be used to...